Workday Inc (NASDAQ:WDAY) shares gained 9% to about $238 in early trading on Wednesday after activist investor Elliott Investment Management revealed that it has purchased a more than $2 billion ownership interest in the human resources software provider.
Instead of calling for major changes in the company, Elliott instead praised the leadership of Workday.
Lyft Inc (NASDAQ:LYFT) shares popped after it announced a partnership with Waymo to introduce fully autonomous ride-hailing services in Nashville starting in 2026.
Under the agreement, Lyft’s Flexdrive division will oversee management of Waymo’s autonomous vehicle fleet, including maintenance, charging infrastructure, and depot operations.
Nano One Materials Corp (TSX:NANO, OTC:NNOMF) announced that Japan’s Sumitomo Metal Mining Co Ltd has confirmed Nano One as a key technology partner as it advances its growth strategy for lithium iron phosphate (LFP) cathodes.
Nano One said results from development work and trials, economic modeling and IP review have been positive, thus giving Sumitomo Metal Mining a high degree of confidence in Nano One's proprietary One-Pot LFP technology.
Nvidia Corp (NASDAQ:NVDA, ETR:NVD) shares fell 1.3% in premarket trading on Wednesday after Chinese regulators reportedly extended a ban on the country’s technology giants from buying AI chips from the US company.
According to a Financial Times report, the Cyberspace Administration of China said the companies, including TikTok owner ByteDance and e-commerce giant Alibaba Group (NYSE:BABA), should stop testing and ordering special China-only AI chips that Nvidia makes with slightly limited capabilities.
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares jumped 26% after the biotech reported encouraging early results from its phase I trial of HG-CT-1, an experimental CAR-T therapy for relapsed or refractory acute myeloid leukaemia (AML).
The London-listed company said its third patient had been treated successfully, with the therapy meeting initial safety targets and showing signs of efficacy.